Zinman B, Aroda VR, Buse JB, et al. - Researchers tested the effectiveness, safety and tolerability of oral semaglutide added to insulin ± metformin in this investigation involving patients with type 2 diabetes (T2D). Participants in the study were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181), or placebo (N = 184) in a 52-week, double-blind trial. Nausea was the most frequent adverse event with oral semaglutide. If added to insulin ± metformin in patients with T2D, oral semaglutide was better than placebo in decreasing HbA_1c and body weight. Other glucagon-like peptide-1 receptor agonists complied with the safety profile.